Difficulty: Medium
Average Score: 66%
Practice
You are evaluating a 6-year-old child with ALL on interim maintenance phase who has frequent mucositis and myelosuppression that needs frequent discontinuation of his treatment. Of the following, the MOST valuable test for this child is
Correct answer
B
Rationale
In the scenario presented, the most valuable test for the 6-year-old child with Acute Lymphoblastic Leukemia (ALL) on interim maintenance phase experiencing mucositis and myelosuppression is pharmacogenetic testing of the thiopurine S-methyltransferase (TPMT) gene, which is option B.
The correct answer is B because pharmacogenetic testing of TPMT gene helps in determining the patient's ability to metabolize thiopurine medications like mercaptopurine, which are commonly used in ALL treatment. Children with certain TPMT gene variants may be at higher risk of developing severe myelosuppression when treated with standard doses of thiopurine drugs. Adjusting the dosage based on TPMT status can help in preventing severe adverse effects and optimizing treatment outcomes.
Option A (complete blood count) is a standard test in monitoring ALL patients but may not provide specific information about drug metabolism like TPMT testing does. Option C (renal function test) is important for assessing kidney function but is not directly related to managing drug toxicity in this case. Option D (bone marrow study) is valuable for assessing disease response and progression in ALL but does not address the issue of frequent treatment discontinuation due to toxicity.
Educationally, understanding the importance of pharmacogenetic testing in pediatric oncology highlights the personalized approach to treatment, minimizing adverse effects, and improving therapeutic efficacy. It underscores the need for comprehensive care in managing pediatric cancer patients, considering both disease-specific factors and individual genetic variations to optimize treatment outcomes.
The correct answer is B because pharmacogenetic testing of TPMT gene helps in determining the patient's ability to metabolize thiopurine medications like mercaptopurine, which are commonly used in ALL treatment. Children with certain TPMT gene variants may be at higher risk of developing severe myelosuppression when treated with standard doses of thiopurine drugs. Adjusting the dosage based on TPMT status can help in preventing severe adverse effects and optimizing treatment outcomes.
Option A (complete blood count) is a standard test in monitoring ALL patients but may not provide specific information about drug metabolism like TPMT testing does. Option C (renal function test) is important for assessing kidney function but is not directly related to managing drug toxicity in this case. Option D (bone marrow study) is valuable for assessing disease response and progression in ALL but does not address the issue of frequent treatment discontinuation due to toxicity.
Educationally, understanding the importance of pharmacogenetic testing in pediatric oncology highlights the personalized approach to treatment, minimizing adverse effects, and improving therapeutic efficacy. It underscores the need for comprehensive care in managing pediatric cancer patients, considering both disease-specific factors and individual genetic variations to optimize treatment outcomes.